Maze Therapeutics, Inc Investor Event Transcript, Nov 17, 2026
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics has completed enrollment in its Phase II Horizon study, with more than 50 patients enrolled. An administrative analysis showed clear UACR reduction across a broad spectrum of patients and a response rate over 50%. The company said it has data in early 2027 and that its capital funds those catalysts into 2029. AI summary
Conference Transcript - MAZE 2026-11-17
Operator
Good afternoon, everyone, and welcome to the Jefferies 2026 Global Healthcare Conference in London. It's my great pleasure to introduce Jason Coloma, CEO of Maze Therapeutics.
Jason Coloma, CEO
Thank you. Hi, I am Jason Cloma. I'm the CEO of Maze Therapeutics. First of all, I'd like to thank the Jeffries team for having us at this year's conference. Just acknowledge our forward-looking statements. At Mays, our mission is to harness the power of human genetics to transform the lives of patients. For those not familiar with our story, we are a clinical-stage biopharmaceutical company focusing on novel, small-molecule precision medicines to diseases that haven't seen it before, like chronic kidney disease. We have expected a runaway into 2029. We have multiple programs, multiple data catalysts coming, and the cash envelope to really be able to fund and deliver that for us and our shareholders. I'm extremely proud of the slide that you see here, as it represents all the hard work of our scientists and our team. We've been developing a best-in-class molecule in 8-Ball-1 kidney disease. For those not familiar with the disease, about a million individuals in the U.S. alone suffer from having the variant and potentially having kidney disease. There's at least 250,000 that have a high enough level of proteinuria where they can benefit from an 8-Ball-1 inhibitor. There are only three programs in development today. We are finishing our Phase II Horizon study. We've completed enrollment with data in early 2027. Another small molecule program, our SLC6A19 inhibitor, which we're developing for two indications, one in a rare metabolic disease called PKU, where we demonstrated, again, potential best-in-class properties relative to what's been described in the literature to date. That study is enrolling, as we speak, in CIFR, and we expect to have data in 2027. We've also been developing the concept, as we are the first company to develop the genetic relationship of SLC inhibition in the context of chronic kidney disease, and we demonstrated proof of mechanism in an early development study. We are looking to launch that study in 2027, where we'd like to show protein or a reduction, as well as be able to try to demonstrate, for the first time, the potential of a biomarker That might be able to be helpful in the development and identifying patients that might see a better effect size. Now, we have had a very productive research engine over time. We have the ability to carry some of those programs forward ourselves like we have with our 841 program as well as our SOC program, but we've also demonstrated the capability to have leverage through partnership, including our partnership with Shinogi where we are developing our Pompeii program and advancing that as they're completing the phase two enrollment. Now based off of the cash that we've been able to raise either through partnership or through Through equity financing, we do have the capital to fund all of these particular data catalysts that we've been describing, as well as be funded into 2029. Now, I'd like to turn our attention to April 1 kidney disease. It is our lead program. And those that are not familiar with the kidney disease that's caused by April 1, now, one thing is that most people associate chronic kidney disease or some form of kidney disease with an elderly population. It turns out 8-0-1 kidney disease affects a more younger generation of patients. They end up having more severe or progressive disease, meaning that they transition into end-stage renal disease and even into dialysis about 10 years earlier than those that don't have the variant. And unfortunately, as we know today, that standard of care, including things like ACE-ARBs and SGLT2 inhibitors, which were important for kidney disease treatment today, are very ineffective in being able to slow down the progression to end-stage renal disease. So the idea of us, as well as other sponsors, was to identify a disease-modifying approach with 8.001 inhibition directly, and if we're able to do that, we might be able to prevent not only the transition to end-stage renal disease, but hopefully that transition that they'll never have to enter dialysis ever in their life. Now, how does APL1 cause disease? And what you can see on the diagram here on the left is that concept of being able to think about under certain conditions, what we know now today is that you have this overexpression of the APL1 pore in the podocyte, which is basically a kidney cell. And under those conditions, what you can see there in those pairings of those particular pore is that they're ungated. So not only do you have basically these pores punching holes in the cell membranes of those kidney cells, but they're also ungated such that they're causing this influx of the blue dots that you see here, which are these cations, causing eventually toxicity in the kidney. Now, what is interesting is to think about how you might be able to have a disease-modifying therapy, and so what we realize is that, at minimum, you want to be able to block the pore so that you don't have this influx of the cations causing the nephrotoxicity, but it also makes sense, in the sense of understanding the biology, that we might be able to prevent the formation of those pores from ever forming it to begin with, and that's what you see here on the right. It's not only do we have the ability to block the pore, because we are a pore inhibitor, we have differentiated, relative to any mechanism that's been described in the literature to date, the ability to disrupt the pore from forming. And that's important, because if you understand the biology, it turns out that 8.1 rapidly turns over in the podocyte, in the kidney cell, even less than 40 minutes. And so the idea is that you not only want to block it, but you want to disrupt the assembly, and hopefully they never form to begin with. Now, in terms of the patient population, we have a better understanding of the epidemiology, at least in the United States. There's at least a million individuals that have the variant, but with the number that you see here of at least 250,000 individuals split up by the pie chart demonstrated here, is that those are the individuals that probably have a high enough proteinuric level where an 8.1.1 inhibitor can reap clinical benefit. So in terms of the split, FSGS, which is a pretty rare form of kidney disease, comprises some of those patients. But more importantly, broad AMKD, both with or without diabetes, represents the large swath of opportunity as you think about the patient population. Now, a disease that people have been following the kidney development area to probably a little bit more familiarity, IGA nephropathy, which is about 150,000 to 100,000 patients individual. But what you see here in AMKD is less competition, so to speak, in the sense that there are no approved therapies. There is nothing, there are only three companies, and right now we're in later stage clinical development. And so the opportunity to develop what could be the first approved therapy creates an opportunity for us as well as for the patients. Now, we've completed enrollment in what we call our Phase II study, which is the Horizon Study. And if you see here on the top left, what we have is sort of the diagram that kind of describes what we're doing. We screen. So you have to have the variants of APR1 that cause disease. So you either have to be, there's only two, fortunately. There's G1 and there's G2. So you have to be homozygous, or have two copies of the G1 or G2. Or it could be compound One heterozygote, which just means you have one copy of each. Okay, so we treat for three months, then we follow up for a month to see if the treatment effect is there. We've had the baseline cutoff at 200 mg per gram, UACR, the proteinuria level, and what we're doing in Horizon is really to be able to identify the patient populations beyond the rare FSGS, where there has been truly demonstrated proof of concept, that we might be able to incorporate in a later stage pivotal study. So could we include both the broader patient population, including those with or without diabetes? The endpoints are here, safety and tolerability. We've demonstrated to date, based off of our data and our information, a well-tolerated molecule. And we'll look at, in terms of efficacy, UACR, which is basically the urinary albumin to creatinine ratio, which is a measure of how much protein is in the urine. And what we want to be able to do is reduce that at least a certain percentage, at least 30 percent in terms of UACR reduction. Now, in terms of our initial results, we had an administrative analysis that we had earlier this year, which really was to start to look at, one, do we have a competitive profile, in particular in FSGS patients, and secondarily, are there other patient populations beyond FSGS that we might want to incorporate and investigate in a more of a pivotal study? So what we demonstrate is clear UACR reduction across a broad spectrum of patients. The data does clearly support the idea that it could be competitive in FSGS and maybe even in broader AMKD, and I think what we saw is an initial signal in diabetes, albeit more modest, that we can look at are there different particular enrichment strategies where we can better understand the patients who are responding to an APOL1 inhibitor in diabetes patients and consider those patients for an eventual pivotal stage. So the summary is outlined here, and I think just a couple things to kind of point. This is a once-a-day therapy as a concept that's going to be important, in particular for cardiorenal patients. They tend to be what's called polypharm, meaning they're on more than one agent at a time. And so the idea that you have once-a-day convenient dosing will be important. We did show a good safety tolerability profile, both in our Phase I and our initial Phase II safety, and we started to show the efficacy data across the entire cohort. One in FSGS showing what's been described as potentially best-in-class relative to what's been described in the literature to date at a certain percentage of UACR reduction, and then broadly what we want to be able to show across the entire Horizon cohort and the whole entire study is at least a 30% reduction across all of the patients that are being explored in the study. So if you note here, in particular, those that don't have diabetes, a pretty dramatic reduction. If you look at this waterfall part in front of you, in terms of the amount of UACR reduction, this is just an administrative analysis of which we will have further and more patients in the full readout. But at least it gave us a reason to believe that we could have a competitive profile on the amount of UACR reduction relative to what's been described in the literature to date. We did have a response rate over 50%, which was one of our goals. And in particular, in the FSGS patient population that you can see in the asterisks here, you can see a pretty dramatic reduction of proteinuria relative to what's been described in the literature to date. Now, when you look at the entire cohort, which we wanted to do a couple things, which is one, across all the patients, including diabetes, we wanted to be able to see at least a 30% reduction. You can see that we've met that. We wanted to see at least a 50% response rate and being able to see that, and I think at least when it comes to diabetes patients, we wanted to see, do we see any signal at all, and are there going to be different ways that we might be able to enhance for that signal, Either through additional biomarker work or maybe just even just by looking at different things like proteinuria levels, which might be able to distinguish the patients we enroll in a subsequent study. And so the reason to believe, in particular for diabetes patients, a couple case studies here, which I think are informative as we think about the patient profiles that might be involved in a further study. One is that we wanted to see here the ability to see benefit on top of current standard care in diabetes patients. That includes SGLT2 inhibitors, which has become an important anchor for kidney disease treatment today. And the other, which is obviously very notable, is GLP-1. And you can see that in both the patients, at least as case studies, the ability to reduce protein area pretty significantly, and being able to do it at a percentage of above 30%, that allows us to really give that indicator that you can see long-term renal protection with an APL1 inhibitor. So in terms of our next steps for MZE 829, we have completed enrollment for the Horizon study. We had promised our investors and ourselves the ability to have, across three particular cohorts, 10 to 15 patients per cohort. We've exceeded that. We have more than 50 patients that we've been able to enroll into the study. So if you do the math, 10 to 15 meant 30 to 45. We've exceeded that in terms of more patients enrolled than expected. I think part of that is just the increased awareness of the disease, the increased infrastructure that's been occurring in terms of testing capability and access, and also I think what was very helpful as we were working with the community at large was having some initial data, including some of the data that we showed today, that really shows a reason to believe that patients who are not responding to current standard of care might benefit from an 8-Ball-1 inhibitor. So we've seen the enrollment pick up quite significantly. That only now gives us the confidence that we can enroll a study the size of studies of other sponsors that have also run phase two, and more importantly, give us the confidence that we'd be able to enroll the next study, which is the pivotal. Now, in terms of the data, we said that we would have data in early 27 on track to deliver that and, of course, be able to start a study in 2027. Now, our second program, which is targeting a solute transporter called SLC6A19, also a small molecule, which we started a PKU study earlier this year, built off of our preclinical data that showed we had reasons to believe that we can have a best-in-class molecule relative to what's been described in the literature to date in front of us, as well as be able to show that we could potentially work across an entire spectrum of PKU patients, Even those that might be on existing therapies like BH4 cofactors. Now, for those not familiar with PKU, it is a rare metabolic disease which, left untreated, creates severe cognitive defects in particular patients, particularly those in the patients that are not able to have their diets controlled. What ends up happening is they have an amino acid, phenylalanine, that accumulates in the blood, and it becomes a toxic accumulation such that some of that phenylalanine makes its way to the brain, ultimately causing that neurocognitive effect. So the idea is right now that unfortunately patients have to be on a pretty onerous medical diet that reduces the total amount of protein. People that have a more severe form of that disease, they can have about 10 grams of protein a day. If you think about that, that's about two eggs. So imagine that is the entire amount of protein one can take a day, and obviously the ability to more normalize their diets and live a more healthier life is what we can do with a PKU drug. The idea here is rather than think about replacing the enzyme that could potentially get rid of the phenylalanine in the blood or maybe use a cofactor, which is what cuvan and suffiance are, that really enable the residual enzyme that's present to be more effective at reducing that plasma fee. SLC inhibition provides a new orthogonal approach that doesn't rely on the enzyme. We can get rid of the plasmaphyl accumulating in the blood by basically hitting the target, and patients end up urinating the phenylalanine out. Now, that's good in the sense that it really could address the entire spectrum of disease here. And we know that most patients represented by this pie chart that you see here are not even on a therapy. They are on medical diet, and if you've ever experienced it or even smelled the medical diet, it's horrible for patients. And the idea that they can eventually normalize their diets and have more protein is a dream of their patients, as well as the parents of those patients. So the idea in the red is that we could potentially provide a therapy for those patients that don't respond. The second is enzyme substitution therapy, which is really focused on replacing the enzyme that enables the breakdown of phenylalanine in the blood. Unfortunately, it does have a box warning, so some patients, including PEDS, can't take it. Some patients aren't able to stay on drug because you have waning efficacy because of the antibodies generated against the enzyme. And so the idea is that we could potentially replace the therapy there. The last, which is there are cofactors which enable the residual enzyme to be more effective. So that's Kuvan or Suffiance, which has had a very successful launch. But not all patients, that's the dark blue here, not all patients respond. And more importantly, there are patients who can have some level of response, but not necessarily have enough of an effect that they can get off the medical diet. So one could think about and imagine our therapy in combination that allows us to really be able to get patients off the medical diet. So in terms of the mechanism, a person who doesn't have PKU, you can see that here on the left, which is basically they have enough of the enzyme or they have cofactor to that enzyme that allows the patient to be able to break down the phenylalanine in the blood. You can see two things here in the diagram. Red is blood, yellow is urine, the green dots represent the phenylalanine, and in a normal individual, they're basically able to break down that phenylalanine in the blood. That what happens in a PKU patient is, unfortunately, they don't have enough of the enzyme, or they don't have enough of the cofactor, and you can see that accumulation of the green dots and the red, and unfortunately, those particular things end up in the brain, which cause the issues in terms of the neurocognitive deficiencies. And so the idea with SOC inhibition, as opposed to any other therapy that's been described before, is to hit the target, SOC, and effectively what you're doing is urinating out the excess phenylalanine that's accumulating, and eventually you can use that, and importantly you can use that in terms of the urine, to use that as a pharmacodynamic marker, even in healthy volunteers. So our phase one did support that. Not only were we looking at safety tolerability, well tolerated based off what we presented previously. We had the ability to kind of think about different formats, whether that be once a day or twice a day, depending on what we wanted to do. And then also we were able to measure phenylalanine as it was treated into the urine as a pharmacodynamic marker and compare that to what has been described in literature to date to reinforce the concept that we have the potential to be best in class. And we showed that exactly in our phase one. So what you see here is our SAD and our MAD. I'd like you to pay attention to our MAD data here on the right, which is if you look at the X-axis, that's what we were doing in terms of the different doses. The y-axis is basically how much of the urinary fee is actually being excreted into the urine. And then pay attention to the gray dotted line at the 10, which is what the literature had described as, at the time, the amount of urinary fee of a competing molecule. And you can see here on our math data that we had multiple doses to exceed that tenfold increase in urinary fee, starting to demonstrate we have best in class. We also did that at multiple doses, and even, you know, the doses we end up carrying forward into our phase two significantly so.
Operator
There we go.
Jason Coloma, CEO
All right, so we are in the process. We have started our phase two called CIFR for MZE7A2. If you can look here at the schematic, what we do is there's a placebo-controlled. We are looking at a low dose described here, a high dose, and we're also looking at a combination with the BH4 agonists, I'm sorry, BH4 cofactors that allows us to kind of think about combination as a potential solution for patients. So we do screen, we randomize, double-blind, open-label period, and the follow-up for safety. A couple of things that we're interested in looking at, of course, is what dose we would carry forward in terms of the pivotal. From a safety tolerability is another to reinforce what we saw in our phase one. And then from an efficacy standpoint, we want to look at a couple of things that are important for the patient. Number one, what is the percentage of plasma feed that is actually being reduced in the PKU patients? What the literature had described previously is at least a 40% reduction of plasma fee, at least to demonstrate POC. We have reasons to believe we can beat that. And the other thing is how many patients or the percentage of patients that can get below a certain threshold of plasma fee in the blood. And we've defined that as 360 micromolars per liter of plasma fee, as well as the number of patients that can get below 120. And why do those numbers matter? Those are the thresholds. One could start as a physician to transition patients off of the onerous medical diet and start to think about truly liberalizing their diets. Okay, and so the previous literature, again, had described at least a 40% reduction of hitting. You hit SLC, and it drops at at least 40% in terms of plasma fee, and the literature had described a certain percentage of patients. The treatment had showed three of the 19 got below 360, and one of the 19 got below 120. So nice that they had shown proof of concept, but we think based off of our previous early development data, we have reasons to believe we can be best in class. Now, we're also developing SOC inhibition in the context of chronic kidney disease. We described and published on the genetic relationship, not just at a genome-wide association, but looking at particular variants of the gene that implicate that it could be protective for certain individuals, not from transitioning to end-stage renal disease. So we wanted to be able to kind of think about what is the level of inhibition that we might be able to think about to show that, Reinforcing what we showed preclinically and through the genetics, and could we show proof of mechanism even in healthy volunteers that gives us reasons to believe in terms of confidence to start a phase two for chronic kidney disease? So if you think about chronic kidney disease in a more classical sense, we know that therapies like SGLT2 inhibitors have become an important anchor, an important pillar in the way that patients are treated. But unfortunately, not all patients respond. More than 25% of the patients don't see any response to SGLT2s. And several of those particular patients have to come off of the therapy for various reasons, including hypoglycemia and what patients call brain fog, which is basically at a level that it becomes a detriment and they can no longer take the therapy. And so the idea here is that we have a therapy that doesn't rely on lowering glucose levels as opposed to an SGLT2. We have an orthogonal mechanism that might have the benefit of working in those particular patients and be able to be yet another tool in the toolkit for a renal physician to treat chronic kidney disease. Now, in terms of mechanism, we have two prevailing thoughts on how this could potentially be having a renal protective effect. And it's important to note, for those that are unfamiliar with this, is that all therapies that have been improved for chronic kidney disease that demonstrate a renal protective effect or just showed protection had this phenomenon called an EGFR dip. And over time, that did better than placebo, showing renal protection. Now, it's a little counterintuitive because EGFR, if you go in for a basic lab test, that's really to test your glomerular filtration rate. And ideally, you want that up. You want that higher, showing that you have a better, more functioning kidney. Now, it turns out that things like SGLT2, ACE, ARBs, even GLP-1s, they show this initial EGFR dip, showing what's called a hemodynamic effect. But over time, it actually does better than placebo. And that's one of the things that's been pretty well demonstrated. So investigators and us, as we sat down, said, if we actually have a hemodynamic effect, we'd want to even see that in healthy volunteers because we know all approved therapies can show that, even in the phase one. The other thing is that we started to describe is that we not only do have a very similar mechanism to SGLT2, but we also have this impact in terms of toxic metabolites that we might be able to handle by SLC inhibition. So if you see here in the middle panel here, that red smudge is really that SLC is responsible for other cargos other than phenylalanine, which was important for our PKU part of the story. It turns out some metabolites in excess in this part of the kidney are toxic. And so if you inhibit the target, you end up, just like you do with the phenylalanine, you end up urinating it out, and that ends up being beneficial to the patient. So not only could we have the benefit of an SGLT2 with the hemodynamic effect, but we also have this orthogonal mechanism that removes the toxic accumulation of certain metabolites in that region of the kidney. Now, so how do we think about measuring that, even in healthy volunteers? So we now know, of course, the literature had described the fact that you can see an EGFR dip, even in healthy volunteers, SGLT2 should, as I mentioned earlier. And so what you see here on the left part of the panel is you see a dose-response relationship between EGFR dip and the doses, which is important. And on the right, a couple things to point out. You see on the XS, that's more of the amount of time that people were treated. On the Y is really the EGFR slope change. And what you can see is a couple things. One is that you do see this type of relationship at this dose over the treatment period. You see it. You don't see that in the placebo. The second thing that's important is in the range of SGLT2, as signified by that red banner across the graph there. And the third is when we pull patients off of treatment, you can see the bounce back, which is important because then the EGFR dip is attributable to the treatment, not necessarily anything else. So I think those, in summary, start to demonstrate and reinforce what we saw in the preclinical and the genetics analysis that we could have this type of proof of mechanism and demonstrate that we can do this even in patients. Now, in terms of how we think about... Oh, okay. So I think I was told to stop. So in terms of Maze Therapeutics, thank you for the time today in the sense of being able to... We have two programs, multiple catalysts, data coming out several times over 27. We have the cash envelope to deliver on all of that particular data, including the ability to start our pivotal study around AMKD. I appreciate your time, and I hope you have a great rest of your conference. Thank you.